RxDoctor Payments Data

Thomas Earl, MD

Interventional Cardiology · Bangor, MENPI 1992920508

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,769 of the $2,826 with a category attached, or 62.6%. Boston Scientific accounts for 62.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $1,635 and has fallen 94.8% since, to $86 in 2025.

$2,826in general payments, 2019–2025

Across 44 payments — averaging $64.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$403
  • Abiomed$163
  • Abbott$139
  • Siemens Medical Solutions USA, Inc.$138
  • Shockwave Medical, Inc$86
  • plus $141 from 6 others
$7,725in research payments, 2019–2025

Across 53 payments — averaging $145.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotronik Inc.$8K

What the payments were for

  • Travel & lodging$1,05737%
  • Food & beverage$1,76963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,826 in reported general payments places this provider in the 60th percentile of 21 interventional cardiology providers in Maine.

See all interventional cardiology providers in Maine

Medicare billing

Part B allowed, 2024
$91,868
Medicare patients
613
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate15$165
Atorvastatin Calcium12$140

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Bangor

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →